<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="833">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924871</url>
  </required_header>
  <id_info>
    <org_study_id>deep extubation in CAUH</org_study_id>
    <nct_id>NCT01924871</nct_id>
  </id_info>
  <brief_title>Comparison of Deep Extubation During Emergence Using Desflurane or Desflurane With Remifentanil in Patients Undergoing General Anesthesia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Ang University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung-Ang University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been reported that deep extubation can reduce cardiopulmonary complication against
      endotracheal tube extubation during emergence from general anesthesia. The investigators
      hypothesized that using desflurane with target controlled infusion of remifentanil is more
      effective than using desflurane alone during deep extubation. The purpose of this study is
      to evaluate the effect of remifentanil to prevent respiratory complication (etc. coughing)
      during emergence from general anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Awakening Time</measure>
    <time_frame>Participants will be followed from the time of extubation in operating room to the time of discharge from recovery room, an expected average of 1day.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The outcomes assessor will record from the time of extubation in operating room to the time of eye opening and mouth opening</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success Rate &amp; Complication Rate Including Cough</measure>
    <time_frame>assessing the success rate of deep extubation without complication and the occurrance of cough from the completion of surgery to 5minute after extubation.</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess the success rate of deep extubation without complication and the occurrence of cough during emergence from general anesthesia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>Participants will be followed for the duration of postanesthesia care unit (PACU) stay, an expected average of 1 hour.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The outcomes assessor will evaluate the degree of postoperative pain using a numeric rating scale (NRS). (0 = no pain, 10 = unimaginable severe pain)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Deep Extubation</condition>
  <arm_group>
    <arm_group_label>Desflurane group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 MAC desflurane until extubation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desflurane with remifentanil group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane with remifentanil</intervention_name>
    <description>During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil</description>
    <arm_group_label>Desflurane with remifentanil group</arm_group_label>
    <other_name>desflurane with remifetanil group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane</description>
    <arm_group_label>Desflurane group</arm_group_label>
    <other_name>Desflurane alone group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-60

          -  patients undergoing elective surgery take more than an hour

          -  Under general anesthesia using an LMA

          -  ASA I,II

        Exclusion Criteria:

          -  Patients on CNS depressants

          -  Chronic opioid use

          -  Corticosteroid

          -  Pregnant patients

          -  Full stomach

          -  Morbidly obese (BMI &gt;35kg/m2)

          -  Hepatitis B

          -  Hepatitis C

          -  Coronary artery disease

          -  Liver disease

          -  Renal disease

          -  Seizure disorder

        Dropout criteria:

          -  Need for reintubation due to breath holding

          -  high ETCO2 during self ventilation (ETCO2&gt;50)

          -  Surgeon or patient request
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>August 12, 2013</firstreceived_date>
  <firstreceived_results_date>April 4, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung-Ang University Hospital</investigator_affiliation>
    <investigator_full_name>Chongwha Baek</investigator_full_name>
    <investigator_title>Chongwha Baek, MD, Ph.D</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Desflurane Group</title>
          <description>1.5 MAC desflurane until extubation
Desflurane: During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane</description>
        </group>
        <group group_id="P2">
          <title>Desflurane With Remifentanil Group</title>
          <description>1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
Desflurane with remifentanil: During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Desflurane Group</title>
          <description>1.5 MAC desflurane until extubation
Desflurane: During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane</description>
        </group>
        <group group_id="B2">
          <title>Desflurane With Remifentanil Group</title>
          <description>1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
Desflurane with remifentanil: During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38.76" spread="11.53"/>
                <measurement group_id="B2" value="43.24" spread="9.39"/>
                <measurement group_id="B3" value="42.17" spread="10.58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Awakening Time</title>
        <description>The outcomes assessor will record from the time of extubation in operating room to the time of eye opening and mouth opening</description>
        <time_frame>Participants will be followed from the time of extubation in operating room to the time of discharge from recovery room, an expected average of 1day.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Desflurane Group</title>
            <description>1.5 MAC desflurane until extubation
Desflurane: During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane</description>
          </group>
          <group group_id="O2">
            <title>Desflurane With Remifentanil Group</title>
            <description>1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
Desflurane with remifentanil: During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Awakening Time</title>
            <description>The outcomes assessor will record from the time of extubation in operating room to the time of eye opening and mouth opening</description>
            <units>minutes</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10" lower_limit="8.5" upper_limit="10.5"/>
                  <measurement group_id="O2" value="7" lower_limit="6" upper_limit="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate &amp; Complication Rate Including Cough</title>
        <description>We will assess the success rate of deep extubation without complication and the occurrence of cough during emergence from general anesthesia.</description>
        <time_frame>assessing the success rate of deep extubation without complication and the occurrance of cough from the completion of surgery to 5minute after extubation.</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Postoperative Pain</title>
        <description>The outcomes assessor will evaluate the degree of postoperative pain using a numeric rating scale (NRS). (0 = no pain, 10 = unimaginable severe pain)</description>
        <time_frame>Participants will be followed for the duration of postanesthesia care unit (PACU) stay, an expected average of 1 hour.</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Desflurane Group</title>
          <description>1.5 MAC desflurane until extubation
Desflurane: During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane</description>
        </group>
        <group group_id="E2">
          <title>Desflurane With Remifentanil Group</title>
          <description>1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
Desflurane with remifentanil: During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Chong Wha Baek</name_or_title>
      <organization>Chung-Ang University Hospital</organization>
      <phone>82-2-6299-2579</phone>
      <email>nbjhwa@naver.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
